WGS Stock Forecast & Price Target

GeneDx Holdings Corp is experiencing robust growth in its core exome and genome testing segments, with a notable 65% year-over-year increase in revenue and a significant 23% rise in average selling price (ASP) to $3,850 per test. The positive mix-shift towards exome/genome based panels is expected to enhance both average selling prices and gross margins, with the latter projected to reach 70%-71%. Additionally, the company has revised its 2025 revenue guidance upward, now anticipating between $425 million and $428 million, reflecting strong demand and strategic realignment in its sales approach targeting pediatric neurologists.

GeneDx Holdings Corp faces significant financial challenges, including an anticipated cash burn of approximately $2 million per quarter related to its whole genome sequencing (WGS) operations. The company is currently experiencing a high denial rate of 45% for third-party payer reimbursements, which could substantially hinder its commercial success if these conditions do not improve, despite being contracted with around 80% of health plans. Additionally, any disruptions to its data and workflow services could further negatively impact its financial stability and operational results, underscoring the risks associated with its current business model.